CRISPR Therapeutics logo

CRISPR Therapeutics AG (NASDAQ:CRSPGet Rating) shares saw an uptick in trading volume on Wednesday after Piper Sandler raised their price target on the stock from $115.00 to $121.00. Piper Sandler currently has an overweight rating on the stock. 69,130 shares changed hands during trading, a decline of 96% from the previous session’s volume of 1,732,344 shares.The stock last traded at $57.02 and had previously closed at $64.67.

A number of other equities analysts have also weighed in on CRSP. Needham & Company LLC lowered their target price on CRISPR Therapeutics from $170.00 to $122.00 in a research report on Friday, May 13th. Credit Suisse Group assumed coverage on CRISPR Therapeutics in a report on Thursday, April 28th. They set a “neutral” rating and a $78.00 price target for the company. StockNews.com assumed coverage on CRISPR Therapeutics in a report on Thursday, March 31st. They set a “sell” rating for the company. Oppenheimer decreased their price target on CRISPR Therapeutics from $172.00 to $150.00 in a report on Wednesday, May 11th. Finally, Royal Bank of Canada decreased their price target on CRISPR Therapeutics from $95.00 to $85.00 in a report on Tuesday, May 10th. One analyst has rated the stock with a sell rating, six have issued a hold rating and eleven have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $116.19.

(Ad)

The U.S. and China are fighting for new sources of lithium – the linchpin of clean energy. Lithium mining operations have been declared a national emergency. Biden has ordered America’s lithium supply chain to be strengthened and investors in lithium exploration companies are rejoicing. We may be entering a decades-long lithium bull run. You don’t want to miss it.

Hedge funds have recently bought and sold shares of the company. Capital Impact Advisors LLC bought a new position in shares of CRISPR Therapeutics during the 4th quarter worth $26,000. Elkhorn Partners Limited Partnership grew its stake in shares of CRISPR Therapeutics by 180.0% during the 4th quarter. Elkhorn Partners Limited Partnership now owns 350 shares of the company’s stock worth $27,000 after acquiring an additional 225 shares during the period. Kistler Tiffany Companies LLC grew its stake in shares of CRISPR Therapeutics by 6,250.0% during the 4th quarter. Kistler Tiffany Companies LLC now owns 381 shares of the company’s stock worth $29,000 after acquiring an additional 375 shares during the period. IronBridge Private Wealth LLC bought a new position in shares of CRISPR Therapeutics during the 4th quarter worth $30,000. Finally, First PREMIER Bank bought a new position in shares of CRISPR Therapeutics during the 1st quarter worth $31,000. Institutional investors own 56.12% of the company’s stock.

The company has a market cap of $4.42 billion, a P/E ratio of 16.11 and a beta of 2.04. The firm has a 50 day moving average price of $57.37 and a two-hundred day moving average price of $63.16.

CRISPR Therapeutics (NASDAQ:CRSPGet Rating) last issued its quarterly earnings data on Monday, May 9th. The company reported ($2.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.94) by ($0.38). The company had revenue of $0.94 million for the quarter, compared to analysts’ expectations of $2.45 million. CRISPR Therapeutics had a return on equity of 12.77% and a net margin of 34.04%. The business’s revenue for the quarter was up 74.4% on a year-over-year basis. During the same period last year, the company posted ($1.51) EPS. As a group, sell-side analysts forecast that CRISPR Therapeutics AG will post -8.99 EPS for the current fiscal year.

CRISPR Therapeutics Company Profile (NASDAQ:CRSP)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in CRISPR Therapeutics right now?

Before you consider CRISPR Therapeutics, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and CRISPR Therapeutics wasn’t on the list.

While CRISPR Therapeutics currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

Source link


The above content is from google feed with the source link mentioned. If you wish to remove the content from here then contact us and it will be removed within 24 hrs.